Steglujan

Steglujan (Ertugliflozin L-Pyroglutamic Acid; Sitagliptin Phosphate Monohydrate) is an advanced treatment option designed to support blood sugar management in adults with type 2 diabetes. This combination works through complementary mechanisms: ertugliflozin helps the body remove excess glucose through urine, while sitagliptin enhances the natural production of insulin in response to elevated blood sugar levels. Together, they offer effective glycemic control, improving overall glucose regulation throughout the day.
Steglujan has been studied in clinical trials for its ability to lower HbA1c levels, providing measurable improvement in long-term blood sugar management. In addition to controlling glucose, it can contribute to mild weight reduction, which is beneficial for individuals managing type 2 diabetes. It also helps maintain stable fasting and post-meal blood sugar levels, reducing fluctuations that may otherwise impact energy and overall health.
Routine monitoring of kidney function, blood sugar levels, and overall cardiovascular health is recommended while using Steglujan. Patients are advised to follow lifestyle measures, including a balanced diet and regular exercise, to enhance the effects of this combination. Its dual-action mechanism has made it a preferred option for adults who need more comprehensive support in managing type 2 diabetes, particularly for those with challenges in controlling blood sugar with a single approach. With careful adherence and regular health evaluations, Steglujan can play a key role in promoting better long-term glycemic outcomes and overall metabolic health.